Cybin Inc. (CYBN): Price and Financial Metrics


Cybin Inc. (CYBN): $0.39

0.00 (0.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYBN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYBN Stock Price Chart Interactive Chart >

Price chart for CYBN

CYBN Price/Volume Stats

Current price $0.39 52-week high $1.16
Prev. close $0.39 52-week low $0.26
Day low $0.38 Volume 1,237,460
Day high $0.40 Avg. volume 1,933,521
50-day MA $0.38 Dividend yield N/A
200-day MA $0.57 Market Cap 72.12M

Cybin Inc. (CYBN) Company Bio


Cybin, Inc. is a biotechnology company that focuses on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. It operates through the following segments: Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.


CYBN Latest News Stream


Event/Time News Detail
Loading, please wait...

CYBN Latest Social Stream


Loading social stream, please wait...

View Full CYBN Social Stream

Latest CYBN News From Around the Web

Below are the latest news stories about CYBIN INC that investors may wish to consider to help them evaluate CYBN as an investment opportunity.

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector 22nd Century announced partnerships with Core-Mark and Eby-Brown, two of the largest U.S. convenience store distributors. Scotts Miracle-Gro announced timing for Q1 financial results and conference call. Tilray’s revenue declines as net losses increase; if cannabis sales continue to be slow, the company may switch to fruit and beer sales. Key […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.

Yahoo | January 24, 2023

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

TORONTO, January 18, 2023--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel ("Kernel"), evaluating Kernel’s Flow® wearable technology to measure ketamine's psychedelic effect on cerebral cortex hemodynamics. Results from this Cybin-sponsored study are intended to inform the future pathwa

Yahoo | January 18, 2023

Trippy Trading: Top Psychedelic Stocks For 2023

When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie...

Yahoo | January 17, 2023

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

TORONTO, January 12, 2023--Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics® today announced that it has selected Generalized Anxiety Disorder ("GAD") with or without major depressive disorder ("MDD") as the target indication for its proprietary deuterated N, N-dimethyltryptamine ("DMT") molecule, CYB004.

Yahoo | January 12, 2023

Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs

TORONTO, January 08, 2023--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today outlined its upcoming priorities and near-term milestones that support the development of its CYB003 and CYB004 clinical programs aimed at addressing multiple mental health conditions.

Yahoo | January 8, 2023

Read More 'CYBN' Stories Here

CYBN Price Returns

1-mo 31.27%
3-mo -15.22%
6-mo -37.10%
1-year -62.86%
3-year N/A
5-year N/A
YTD 31.27%
2022 -75.24%
2021 -19.46%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7033 seconds.